Atovaquone - Wikipedia, the free encyclopedia
A "standard" tablet of Malarone contains 100 mg of proguanil hydrochloride ... Malarone should not be used to treat severe malaria, when an injectable drug ...
http://en.wikipedia.org/wiki/Atovaquone...
|
Malarone (atovaquone and proguanil hydrochloride): a review of its ...
Malarone, a fixed-dose combination of 250 mg of atovaquone and 100 mg of proguanil hydrochloride, is available in many countries for treatment of acute,
...
http://www.ncbi.nlm.nih.gov/pubmed/10348225...
|
Prevention in Children, Public Info | CDC Malaria
Atovaquone/proguanil (Brand Name: Malarone™). Atovaquone/proguanil is a combination of ... It is available in the United States as the brand name,
Malarone. ...
http://www.cdc.gov/malaria/travel/drugs_children_public.htm...
|
Malarone treatment failure not associated with previously ...
28 Jan 2008 ... Malarone® (atovaquone-proguanil) is an effective drug for the treatment and prophylaxis of multidrug-resistant falciparum malaria. ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC425592/...
|
Malarone (atovaquone and proguanil hydrochloride) Tablets
11 Jul 2009 ... Caution is advised when initiating or withdrawing malaria prophylaxis or treatment with Malarone in patients on continuous treatment with ...
http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-...
|
Bullous erythema multiforme after treatment with Malarone, a ...
Bullous erythema multiforme after treatment with Malarone, a combination antimalarial composed of atovaquone and proguanil hydrochloride. ...
http://www.ncbi.nlm.nih.gov/pubmed/18628561...
|
Malarone (atovaquone and proguanil hydrochloride) tablets
19 Oct 2009 ... Malarone (atovaquone and proguanil hydrochloride) tablets Drug Safety Labeling Changes September 2009 - medWatch.
http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm1868...
|
Malarone treatment failure and in vitro confirmation of resistance ...
8 Jun 2004 ... We report the first in vitro and genetic confirmation of Malarone® ( GlaxoSmithKline; atovaquone and proguanil hydrochloride) resistance in ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC111499/...
|
Malarone slide presentation
1. One Year Post-Exclusivity Adverse Event Review: Ciprofloxacin Pediatric Advisory Committee Meeting June 29, 2005. Alan M. Shapiro, MD, PhD, FAAP ...
http://www.fda.gov/OHRMS/DOCKETS/AC/05/slides/2005-4152s1_06...
|
FDA Safety Labeling Changes: Viramune, Copegus, Malarone
20 Apr 2005 ... The FDA has approved revisions to the safety labeling for nevirapine tablets and oral suspension (Viramune), ribavirin tablets (Copegus), ...
http://www.medscape.com/viewarticle/503672...
|
